These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P; J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer. Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004 [TBL] [Abstract][Full Text] [Related]
32. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. Losa A; Hurle R; Lembo A J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316 [TBL] [Abstract][Full Text] [Related]
33. [T1 G3 bladder tumors: the respective role of BCG and cystectomy]. Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369 [TBL] [Abstract][Full Text] [Related]
34. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. DeBruyne FM; van der Meijden AP; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg JJ Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698 [TBL] [Abstract][Full Text] [Related]
35. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
36. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review. Cheng CW; Ng MT; Chan SY; Sun WH ANZ J Surg; 2004 Jul; 74(7):569-72. PubMed ID: 15230793 [TBL] [Abstract][Full Text] [Related]
37. BCG in the management of superficial bladder cancer. Guinan P; Richardson C; Hanna M; Rubenstein M Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002 [TBL] [Abstract][Full Text] [Related]
38. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743 [TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy in superficial bladder carcinoma]. Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392 [TBL] [Abstract][Full Text] [Related]